mTOR inhibitors counteract tamoxifen-induced activation of breast cancer stem cells

作者：Karthik Govindasamy Muralidharan; Ma Ran; Lovrot John; Kis Lorand Levente; Lindh Claes; Blomquist Lennart; Fredriksson Irma; Bergh Jonas; Hartman Johan^*

来源：Cancer Letters, 2015, 367(1): 76-87.

DOI：10.1016/j.canlet.2015.07.017

• Breast cancer stem cells
• Tamoxifen resistance
• mTOR pathway activation

Breast cancer cells with stem cell characteristics (CSC) are a distinct cell population with phenotypic similarities to mammary stem cells. CSCs are important drivers of tumorigenesis and the metastatic process. Tamoxifen is the most widely used hormonal therapy for estrogen receptor (ER) positive cancers. In our study, tamoxifen was effective in reducing proliferation of ER + adherent cancer cells, but not their CSC population. We isolated, expanded and incubated CSC from seven breast cancers with or without tamoxifen. By genome-wide transcriptional analysis we identified tamoxifen-induced transcriptional pathways associated with ribosomal biogenesis and mRNA translation, both regulated by the mTOR-pathway. We observed induction of the key mTOR downstream targets S6K1, S6RP and 4E-BP1 in-patient derived CSCs by tamoxifen on protein level. Using the mTOR inhibitors rapamycin, everolimus and PF-04691502 (a dual PI3K/mTOR inhibitor) and in combination with tamoxifen, significant reduction in mammosphere formation was observed. Hence, we suggest that the CSC population play a significant role during endocrine resistance through activity of the mTOR pathway. In addition, tamoxifen further stimulates the mTOR-pathway but can be antagonized using mTOR-inhibitors.

• 出版日期2015-10-10